Pharmaceutical

BioNxt Signs LOI for Acquisition of IP and Co-Development of ODF Drug Reformulation for Neurodegenerative Disease

VANCOUVER, BC / ACCESSWIRE / August 2, 2023 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to…

12 months ago

Safe Supply Streaming Co. Closes Strategic Private Placement

Vancouver, British Columbia--(Newsfile Corp. - August 1, 2023) - Safe Supply Streaming Co. Ltd. ("Safe Supply" or "SSSC" or "the…

12 months ago

SOHM Inc. Signs LOI to Acquire Stem Cell Disruptive Technology and Patents

CHINO HILLS, CA/ ACCESSWIRE/ / August 1, 2023 / SOHM, Inc. (OTC PINK:SHMN), a generic pharmaceutical, nutraceutical and cosmeceutical company…

12 months ago

Red Light Holland’s Psilocybin Microdosing Homogenized Capsules Receive Finalized Certificate of Analysis by CCREST Laboratories

The natural psilocybin microdosing capsules, developed from psilocybin truffles grown in Red Light Holland's farm in The Netherlands, have received…

12 months ago

Champions Oncology Announces a Multi-Year Agreement and Strategic Collaboration with BioVolume to Transform Reproducibility in Preclinical Oncology Efficacy Studies

HACKENSACK, NJ / ACCESSWIRE / August 1, 2023 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global preclinical and clinical research…

12 months ago

Jaguar Health Announces FDA Activation of Third-Party Investigational New Drug (IND) Application for Evaluation of Crofelemer for Treatment of Uncontrolled Diarrhea in Patient with Short Bowel Syndrome (SBS)

Napo Pharmaceuticals, a Jaguar Health company and the manufacturer of crofelemer, is supporting this physician-generated INDSAN FRANCISCO, CA / ACCESSWIRE…

12 months ago

iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for the Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology

iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of…

12 months ago

CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK

Phase 2 study initiated at clinical sites in Australia with monovalent and bivalent mRNA COVID-19 vaccine candidatesVaccine candidates developed in…

12 months ago

SciSparc and Clearmind Collaboration Continues to Increase its Patent Portfolio in the Field of Movement Abnormalities in the U.S.

TEL AVIV, Israel, Aug. 01, 2023 (GLOBE NEWSWIRE) -- The new U.S. patent application is for the use of the…

12 months ago

Clearmind Medicine Files Patent Application with USPTO for the Treatment of Dyskinesia; Further Strengthens its Already Robust IP Portfolio

Tel Aviv, Israel / Vancouver, Canada, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE:…

12 months ago